No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LQDA Liquidia
- 12.520
- -0.810-6.08%
Close Jun 18 16:00 ET
- 12.560
- +0.040+0.32%
Post 19:09 ET
956.31MMarket Cap-7974P/E (TTM)
13.450High12.500Low1.06MVolume13.300Open13.330Pre Close13.54MTurnover2.47%Turnover RatioLossP/E (Static)76.38MShares16.99052wk High11.09P/B539.50MFloat Cap5.71052wk Low--Dividend TTM43.09MShs Float38.460Historical High--Div YieldTTM7.13%Amplitude2.250Historical Low12.743Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension
Liquidia Insiders Placed Bullish Bets Worth US$3.00m
Liquidia(LQDA.US) Officer Sells US$7,944.3 in Common Stock
$Liquidia(LQDA.US)$ Officer Moomaw Scott sold 546 shares of common stock on Jun 3, 2024 at an average price of $14.55 for a total value of $7,944.3.Source: Announcement What is statement of changes in
Liquidia(LQDA.US) Officer Sells US$10,330.5 in Common Stock
$Liquidia(LQDA.US)$ Officer Schundler Russell sold 710 shares of common stock on Jun 3, 2024 at an average price of $14.55 for a total value of $10,330.5.Source: Announcement What is statement of chan
Liquidia(LQDA.US) Officer Sells US$15,917.7 in Common Stock
$Liquidia(LQDA.US)$ Officer Kaseta Michael sold 1,094 shares of common stock on Jun 3, 2024 at an average price of $14.55 for a total value of $15,917.7.Source: Announcement What is statement of chang
Liquidia(LQDA.US) Officer Sells US$6,620.25 in Common Stock
$Liquidia(LQDA.US)$ Officer Adair Jason sold 455 shares of common stock on Jun 3, 2024 at an average price of $14.55 for a total value of $6,620.25.Source: Announcement What is statement of changes in
Comments
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
12
1
📣 3 PDUFAs left in April! See summary 👇
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
11
4
🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
11
2
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Vanda Pharmaceuticals(VNDA.US$ $Legend Biotech(LEGN.US$ $Supernus Pharmaceuticals(SUPN.US$ $ImmunityBio(IBRX.US$ $Aquestive Therapeutics(AQST.US$ $X4 Pharmaceuticals(XFOR.US$ $Liquidia(LQDA.US$ $Neurocrine Biosciences(NBIX.US$ $Moderna(MRNA.US$ $Day One Biopharmaceuticals(DAWN.US$
...
$Vanda Pharmaceuticals(VNDA.US$ $Legend Biotech(LEGN.US$ $Supernus Pharmaceuticals(SUPN.US$ $ImmunityBio(IBRX.US$ $Aquestive Therapeutics(AQST.US$ $X4 Pharmaceuticals(XFOR.US$ $Liquidia(LQDA.US$ $Neurocrine Biosciences(NBIX.US$ $Moderna(MRNA.US$ $Day One Biopharmaceuticals(DAWN.US$
...
21
2
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
21
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Jimmy1819 : have you been investing professionally or as a hobby?